Literature DB >> 10383007

Preservation of renal function by percutaneous transluminal angioplasty in ischaemic renal disease.

D Paulsen1, N E Kløw, B Rogstad, T Leivestad, B Lien, K Vatne, P Fauchald.   

Abstract

BACKGROUND: The purpose of this study was to evaluate the effects of percutaneous transluminal renal angioplasty (PTRA) on preservation of renal function in patients with bilateral renal artery stenoses or stenosis of the artery of one functioning kidney.
METHODS: A total of 227 PTRAs of 223 stenoses in 135 patients were performed from 1982 to 1993 in a single centre and retrospectively reviewed. The number of PTRAs per patient was 1.7, range 1-6. Angiographical follow-up was performed in 77%, 120+/-82 days after the first PTRA and 273+/-345 days after the last PTRA. Follow-up of serum creatinine and blood pressure was performed in 85% after 414+/-558 days. Long-term follow-up was performed for dialysis, surgical revascularization, renal transplantation and death, mean follow-up 8.8 years, range 5.5-14.8.
RESULTS: The immediate technical success was 90%, and another 5% were improved. The primary patency rate per patient was 43% and the secondary patency rate 64%. Improved renal function was achieved in 23% of the patients, stabilized in 56% and failed in 21%. Stabilized or improved function was higher when baseline serum creatinine was < or =250 micromol/l (85%) than >250 micromol/l (60%). Three of 99 (3%) patients with creatinine < or =250 micromol/l started dialysis during follow-up (41 days, 7.4 and 8 years), as did 13 of 36 (36%) patients with creatinine >250 micromol/l. Blood pressure and the number of antihypertensive drugs decreased in patients with creatinine < or =250 micromol/l, but was unchanged in those with creatinine >250 micromol/l. The 5-year survival rates were 84, 66 and 17% for patients with creatinine <125 micromol/l, 125-250 micromol/l and >250 micromol/l, respectively. Twelve patients (9%) experienced complications, including two deaths.
CONCLUSIONS: Our study shows that PTRA improved or preserved the renal function in most patients with normal to moderately impaired renal function. Close follow-up and possibly re-intervention are necessary to obtain satisfactory clinical and angiographical result.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383007     DOI: 10.1093/ndt/14.6.1454

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Impact of Renal Function Trajectory on Renal Replacement Therapy and Mortality Risk after Renal Artery Revascularization.

Authors:  Edwin A Takahashi; William S Harmsen; Sanjay Misra
Journal:  J Vasc Interv Radiol       Date:  2019-09-14       Impact factor: 3.464

Review 2.  [Renovascular hypertension--diagnosis and therapy].

Authors:  J Riehl; E Spüntrup; B Heintz; R W Günther; J Floege
Journal:  Internist (Berl)       Date:  2005-05       Impact factor: 0.743

3.  Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial.

Authors:  Katherine R Tuttle; Lance D Dworkin; William Henrich; Barbara A Greco; Michael Steffes; Sheldon Tobe; Joseph I Shapiro; Kenneth Jamerson; Asya Lyass; Karol Pencina; Joseph M Massaro; Ralph B D'Agostino; Donald E Cutlip; Timothy P Murphy; Christopher J Cooper
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-25       Impact factor: 8.237

4.  Clinical efficacy of percutaneous renal revascularization with stent placement in hypertension among patients with atherosclerotic renovascular diseases.

Authors:  Seyed Mohammad Hassan Adel; Seyed Masood Syeidian; Mohammad Najafi; Mohammad Nourizadeh
Journal:  J Cardiovasc Dis Res       Date:  2011-01

5.  Pheochromocytoma with renal artery stenosis: A case-based review of literature.

Authors:  Sunil K Kota; Siva K Kota; Lalit K Meher; Prabhas R Tripathy; Jammula Sruti; Kirtikumar D Modi
Journal:  J Cardiovasc Dis Res       Date:  2012-01

6.  Coexistence of pheochromocytoma with uncommon vascular lesions.

Authors:  Sunil Kumar Kota; Siva Krishna Kota; Lalit Kumar Meher; Sruti Jammula; Sandip Panda; Kirtikumar D Modi
Journal:  Indian J Endocrinol Metab       Date:  2012-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.